+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade

Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade

Hellenic Journal of Cardiology 46(5): 324-329

Patients with lung adenocarcinoma often suffer from metastatic pericardial effusion that may eventually cause cardiac tamponade. Recurrence of pericardial effusion is frequent after pericardial drainage and therapy for the prevention of fluid reaccumulation is still controversial. We evaluated the safety and effectiveness of the intrapericardial infusion of cisplatin, a substance with antineoplastic and sclerosing properties, after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Twenty-five patients (19 males and 6 females, median age 55 years) with lung adenocarcinoma confirmed by cytological examination and cardiac tamponade were studied. All patients underwent subxiphoid pericardiocentesis through catheter insertion, under electrocardiographic, echocardiographic and haemodynamic guidance. After the malignant aetiology of the pericardial effusion had been confirmed by cytological examination, cisplatin was instilled (10 mg in 20 ml normal saline) into the pericardial cavity during three consecutive days. Clinical and echocardiographic evaluation was performed every month thereafter. Pericardial fluid of 350-1700 ml was removed (median 750 ml) and was haemorrhagic in 80% of the cases. Paroxysmal atrial fibrillation was detected in three patients (12%) and non-sustained ventricular tachycardia in two (8%). None of the patients had hypotension or retrosternal pain. One patient suffered from significant pericardial effusion reaccumulation (4%). Laboratory findings were not influenced by systemic drug absorption in any patient. Transthoracic echocardiographic study revealed pericardial thickening without physiology of constriction in 4 patients (16%). After pericardiocentesis, the mean survival period overall was 4.5 months (range 3-92 weeks), and mortality was attributed to widespread disease (respiratory failure). Intrapericardial administration of cisplatin is safe and effective in preventing the reaccumulation of malignant pericardial effusion in the majority of patients with lung adenocarcinoma.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 049394659

Download citation: RISBibTeXText

PMID: 16295940

Related references

Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa). American Journal of Cardiology 86(3): 362-364, 2000

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Supportive Care in Cancer 12(1): 53-57, 2003

Evaluation of intrapericardial cisplatin administration in cases of recurrent malignant pericardial effusion and cardiac tamponade. Pneumonologia i Alergologia Polska 64 Suppl 2: 180-186, 1996

eComment: Pericardiocentesis followed by intrapericardial cisplatin administration in patients with neoplastic pericarditis. Interactive Cardiovascular and Thoracic Surgery 10(1): 5-6, 2010

A case of cardiac tamponade due to malignant pericarditis with lung adenocarcinoma, effectively treated with pericardial drainage and pemetrexed plus cisplatin chemotherapy. Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 52(4): 421-424, 2016

Intrapericardial administration of cisplatin in treatment of metastatic pericardial involvement in adenocarcinoma of the lung. Monaldi Archives for Chest Disease 52(3): 221-224, 1997

Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade. World Journal of Gastroenterology 16(6): 740-744, 2010

Intrapericardial cisplatin for malignant tamponade. Revista Espanola de Cardiologia 53(4): 587-589, 2000

Intrapericardial Cisplatin Instillation in Recurrent Postinfarction Cardiac Tamponade. Journal of Cardiothoracic and Vascular Anesthesia 32(1): 458-460, 2017

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer. Lung Cancer 16(2-3): 215-222, 1997

Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis. In Vivo 32(2): 373-379, 2018

Administration of intrapericardial tissue adhesive after cardiac rupture and cardiac tamponade. International Journal of Cardiology 147(3): E50-E52, 2012

Failed pericardiocentesis for acute cardiac tamponade: two cases associated with bivalirudin administration during PCI. Catheterization and Cardiovascular Interventions 75(1): 114-116, 2010

Intrapericardial instillation of mitomycin C in recurrent cardiac tamponade due to malignant pericardial effusion. Clinical Oncology ) 18(6): 506, 2006

Intrapericardial bleomycin for the management of cardiac tamponade secondary to malignant pericardial effusion. British Heart Journal 63(1): 61-62, 1990